Reviews by Demonstration RACs indicated that claims were paid for pharmaceutical injectables with an incorrectly billed number of units; claims paid incorrectly by fee schedule and drugs billed under incorrect HCPCS codes totaled more than $5 million dollars.
Guidance on How Providers Can Avoid These Problems
– CMS published MLN Matters® article 6950, which describes injectable drugs, including intravenously administered drugs typically eligible for inclusion under the “incident to” benefit. MM6950 can be reviewed at http://www.cms.gov/MLNMattersArticles/downloads/MM6950.pdf (pdf) on the CMS website.
– Drug coverage is discussed in Chapter 17 of the Medicare Claims Processing Manual (http://www.cms.gov/manuals/downloads/clm104c17.pdf (pdf)), especially Section 40 (Discarded Drugs and Biologicals), Section 70 (Claims Processing Requirements – General), and Section 80 (Claims Processing for Special Drug Categories).
Recommendations
– Be sure staff is aware of the manual chapter and article cited previously regarding Medicare policy on billing for drugs.
– Ensure you adequately document a physician’s drug orders, dosage administered, and when required by CMS policy, the drug dosage wasted amount.
Source: CMS.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.